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Abstract
Background: Paraneoplastic syndrome generally results from tumor-derived hormones or peptides that cause
metabolic derangements. Common metabolic conditions include hyponatremia, hypercalcemia, hypoglycemia,
and Cushing’s syndrome. Herein, we report a very rare case of tongue carcinoma presenting with leukocytosis
and hypercalcemia.
Case presentation: A 57-year-old man was admitted to our hospital with tongue squamous cell carcinoma
(cT4aN0M0, stage IV). He underwent radical resection following preoperative chemoradiotherapy, but locoregional
recurrence was detected 2 months after surgery. He presented with marked leukocytosis and hypercalcemia with
elevated serum levels of granulocyte colony-stimulating factor (G-CSF) and parathyroid hormone-related protein
(PTHrP). He was therefore managed with intravenous fluids, furosemide, prednisolone, elcatonin, and pamidronate.
However, the patient died 1 month later of carcinomatous pleuritis following distant metastasis to the lung.
Immunohistochemical analyses of the resected specimens revealed positive staining for PTHrP and G-CSF in the
cancer cells.
Conclusions: In this case, it was considered that tumor-derived G-CSF and PTHrP caused leukocytosis and
hypercalcemia.
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Background
Malignant tumors occasionally secrete hormonal factors
that can cause some types of paraneoplastic symptoms
[1–3]. Hypercalcemia is a relatively common paraneo-
plastic syndrome, and recent studies have demonstrated
that parathyroid hormone-related protein (PTHrP) se-
creted by tumor cells can cause hypercalcemia in pa-
tients with malignant tumors [4, 5], while leukocytosis is
a paraneoplastic syndrome caused by tumor-derived gran-
ulocyte colony-stimulating factor (G-CSF) [6]. However,
the paraneoplastic production of both PTHrP and G-CSF
by cancer cells is extremely rare. In this case report, we
present a patient with tongue squamous cell carcinoma
presenting with hypercalcemia and leukocytosis caused by
tumor-derived PTHrP and G-CSF.
Case presentation
A 57-year-old man was referred to the Department of
Oral and Maxillofacial Surgery, Kyushu University, with
a chief complaint of a painful ulcerative lesion on the left
lateral border of his tongue (Fig. 1a). Magnetic
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resonance imaging (MRI) revealed a tumorous mass oc-
cupying half of the tongue on the left side, extending to
the lingual septum, and partially invading into the in-
ternal pterygoid muscle (Fig. 1b). No metastatic lymph
nodes were found in the bilateral neck by palpation,
ultrasonography, or computed tomography (CT). The
patient had a medical history of diabetes mellitus.
Pathological diagnosis of an incisional biopsy specimen
indicated a moderately differentiated squamous cell car-
cinoma (SCC) (cT4aN0M0, stage IV). Planning CT was
carried out followed by preoperative chemoradiotherapy
including external beam irradiation to the primary
tumor and neck in daily fractions of 2 Gy, five times
weekly for 3 weeks, and oral administration of S-1
(120 mg/day) started 1 week prior to radiotherapy and
continued throughout the radiotherapy period. One
month after completing the preoperative chemoradio-
therapy, the tumor was resected by subtotal glossect-
omy and segmental mandibulectomy under general
anesthesia. Modified radical neck dissection and re-
construction using a rectus abdominis myocutaneous
flap were performed simultaneously with tumor resec-
tion. Pathologically, four metastatic lymph nodes were
identified: one in level I, one in level II, and two in
level III. The histopathological response of the pri-
mary tumor to preoperative chemoradiotherapy was
poor, and many residual carcinoma cells were noted
in the muscular tissues in the resected specimens,
though the surgical margin was tumor-free. Locore-
gional recurrence was detected by CT imaging
3 months after surgery, and the patient received fur-
ther chemoradiotherapy (S-1, 120 mg/day; external
a b
Fig. 1 Intraoral and MRI findings. a Tumorous mass with ulcerative lesion on the left lateral border of the tongue. b Contrast-enhanced MRI find-
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Fig. 2 Time course of serum levels of calcium and PTHrP. Serum levels of calcium and PTHrP gradually increased in parallel after the completion
of chemoradiotherapy for locoregional recurrence
Kaneko et al. World Journal of Surgical Oncology  (2016) 14:161 Page 2 of 6
beam irradiation in daily fractions of 2 Gy, five times
weekly for 7 weeks). However, after completion of the
chemoradiotherapy, the patient developed hypercalce-
mia (maximum serum calcium level, 16.3 mg/dL) and
leukocytosis (maximum white blood cell count, 22.7 ×
103/μL). The serum levels of PTHrP and G-CSF in-
creased in parallel with progression of his hypercalcemia
and leukocytosis (Figs. 2 and 3). Immunohistochemical
staining revealed expression of PTHrP and G-CSF in the
residual cancer cells (Fig. 4a, b). Interleukin (IL)-6 expres-
sion was also detected in the cancer cells (Fig. 4c). Based
on these clinical and pathological findings, the patient was
diagnosed with hypercalcemia and leukocytosis associated
with malignancy. He was subsequently managed with
intravenous fluids, furosemide, prednisolone, elcatonin,
and pamidronate. However, an F-18 fluorodeoxyglucose
positron emission tomography (FDG-PET) scan disclosed
multiple metastatic regions, including the pelvis, lung,
femur, adrenal gland, sternal bone, and inguinal nodes,
and he progressed to respiratory failure and died of car-
cinomatous pleuritis 1 month later.
Conclusions
We present a very rare case of a patient with tongue
squamous cell carcinoma presenting with hypercalcemia
and leukocytosis. The serum levels of PTHrP and G-CFS
were markedly elevated in the patient, in line with pro-
gression of his hypercalcemia and leukocytosis. Further-
more, immunohistological staining revealed PTHrP and
G-CSF expression in the residual carcinoma cells. These
findings suggested that hypercalcemia and leukocytosis
in this patient were associated with tumor-derived
PTHrP and G-CSF.
Yoneda et al. reported only five cases (2.2 %) present-
ing with both hypercalcemia and leukocytosis among
225 oral malignancies [7], though they did not demon-
strate if the hypercalcemia and leukocytosis were caused
by tumor-derived PTHrP and G-CSF. To the best of our
knowledge, there have been only 13 recorded cases of
head and neck tumors that produced both PTHrP and
G-CSF, including the current case (Table 1) [8–16], in all
of which patients presented with both hypercalcemia
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Fig. 3 Time course of white blood cell count and serum G-CSF level. The number of white blood cells and G-CSF level gradually increased
in parallel
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Fig. 4 Immunohistochemical staining for PTHrP, G-CSF, and IL-6 in residual cancer cells. (×400). a PTHrP. b G-CSF. c IL-6
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Table 1 Case reports of head and neck tumors producing both PTHrP and G-CSF
No. [ref] Sex Age (year) Primary site Histological type TNM
classification







1 [8] Female 65 Thyroid gland Anaplastic
carcinoma
– – 13.8 142,000 4.02 (<1.1) 318 (<30) Cervix, lung, liver death
2 [9] Male 48 Tonsil SCC – – 11.4 62,100 533.3 (<55.3) 3450 (<30) Cervix, lung, liver, Death
3 [10] Female 63 Thyroid gland Follicular and
papillary
carcinoma
T2N1bM1 Well 13.4 34,700 3.9 196 Lung, bone Death
4 [11] Male 73 Buccal
mucosa
SCC T4N3M1 Poor 15.1 40,200 108.5 (<55.3) 1800 (<30) Lung Death
5 [11] Male 60 Gingiva SCC T4N2M0 Well 18.1 15,800 227.9 (<55.3) 34.3 (<30) Bone, lung Death
6 [11] Male 82 Tongue SCC T3N2M0 Poor 14.7 79,000 132 (<55.3) 274 (<30) Lung Death
7 [11] Male 65 Buccal
mucosa
SCC T4N2M0 Poor 16.2 34,600 255 (<55.3) 211 (<30) Lung, liver, pancreas Death
8 [12] Male 61 Tongue SCC T1N0MX Well 28.5 31,300 3109 (<16) [pg/mL] 285 (<20)
(pleural fluid)
Cervix, lung Death
9 [13] Male 65 Larynx SCC T4N3M0 – 18 60,000 5.6 (<0.5) 222 (<38) Cervix, lung Death
10 [14] Female 57 Hypopharynx SCC T3N2bMX Poor 14.2 46,300 12.4 (<1.1) 111 (<39) Cervix, lung, liver,
bone, kidney, skin
Death
11 [15] Female 32 Mandible Ameloblastoma – – 11.3 37,200 14.7 (<1.1) 68 (<30) – Survive
12 [16] Male 76 Hypopharynx SCC T4aN2cM0 Moderate 11.2 20,230 3.1 (<1.1) 213 (<39) Cervix, esophagus Survive
Present
case
















was the most frequent type of tumor (10 cases, 76.9 %),
but only three cases of tongue squamous cell carcinoma
have been reported [11, 12]. Furthermore, except for a pa-
tient with a benign ameloblastoma, 11 of the 12 previous
cases had a poor prognosis. In the patient with hypophar-
yngeal carcinoma, the serum levels of both PTHrP and G-
CSF were remarkably decreased after radical resection and
the patient was rescued [16]. The present and previous
findings thus suggest that increased serum levels of both
PTHrP and G-CSF are indicative of a poor prognosis in
patients with head and neck tumors.
Hypercalcemia can be categorized as humoral hyper-
calcemia of malignancy (HHM) or local osteolytic hyper-
calcemia (LOH) [17]. HHM is caused by tumor-derived
PTHrP, while LOH is mainly caused by osteolysis associ-
ated with bone metastasis. The present patient demon-
strated multiple bone metastases on FDG-PET with
elevated serum PTHrP levels, suggesting the existence of
both HHM and LOH in this case. The clinical manifes-
tations of hypercalcemia affect the neuromuscular, renal,
gastrointestinal, skeletal, and cardiovascular systems
[18], and anti-hypercalcemic therapy should therefore be
initiated as soon as possible to avoid hypercalcemic crisis
[19]. In this patient, saline infusion (2000–3000 mL/day)
with concomitant loop diuretics (furosemide) was ad-
ministered to increase calcium excretion and reduce
serum levels as rapidly as possible. We also administered
calcitonin (a naturally occurring peptide hormone that
inhibits bone resorption and increases renal calcium ex-
cretion) and a bisphosphonate (alendronate) to treat the
hypercalcemia [20]. Bisphosphonates are effective thera-
peutic agents for hypercalcemia that inhibit osteoclast
differentiation and function [21]. We also used prednis-
olone to reduce gastrointestinal calcium absorption [22].
However, although the patient’s calcium levels were nor-
malized by this therapy, subsequent hypercalcemic ex-
acerbation developed. Yamazaki et al. demonstrated an
average survival period of 39.0 days from the diagnosis
of hypercalcemia in patients with oral cancer treated
with bisphosphonates or calcitonin, compared with
19.5 days in untreated patients [11]. These results sug-
gest that the prognosis of patients with tumor-derived
PTHrP and G-CSF is extremely unfavorable, though
anti-hypercalcemic therapy may slightly improve life
expectancy.
Numerous previous studies have shown that G-CSF is
responsible for paraneoplastic leukocytosis [6, 7, 23–25].
However, the mechanisms responsible for the produc-
tion of these hormonal factors by tumor cells remain
unknown. Recent studies have suggested that some in-
flammatory cytokines, including IL-6, may be associated
with G-CSF production by malignant cells [26]. More-
over, hypercalcemia has been associated with cosecretion
of PTHrP and IL-6 [27]. We previously showed that
increased IL-6 expression in cancer cells predicted a
poor response to chemoradiotherapy and an unfavorable
prognosis in patients with oral SCC [28]. The current
patient demonstrated a poor histological response to
preoperative chemoradiotherapy and strong IL-6 expres-
sion in the residual cancer cells. These results suggested
that IL-6 may play a key role in resistance to chemora-
diotherapy and production of PTHrP and G-CSF in the
cancer cells. However, further in vitro and in vivo studies
are needed to clarify the association between IL-6
expression in oral squamous cell carcinoma and the
production of PTHrP and G-CSF.
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